Abstract:BACKGROUND: Registry-based studies of pediatric pulmonary arterial hypertension (PPAH) are scarce in developing countries, including China. The PPAH risk assessment tool needs further evaluation and improvement.RESEARCH QUESTION: What are the characteristics and long-term survival of PPAH in China and what is the performance of the PPAH risk model in Chinese patients?STUDY DESIGN AND METHODS: Patients with PAH were enrolled in the national prospective multicenter registry from August 2009 through December 2019. Children 3 months to 18 years of age at the time of PAH diagnosis were analyzed.RESULTS: A total of 247 children with PAH were enrolled. The median patient age was 14.8 years, and 58.3% of patients were female. Most patients had a diagnosis of PAH associated with congenital heart disease (CHD; 61.5%) and idiopathic or heritable PAH (37.7%). The median time from symptom onset to PAH diagnosis was 24 months. The mean pulmonary artery pressure and pulmonary vascular resistance index were 70.78 + 19.80 mm Hg and 21.82 + 11.18 Wood Units$m2, respectively. Patients with CHD-associated PAH experienced a longer diagnostic delay and demonstrated higher pulmonary artery pressure, but better cardiac performance, than those with idiopathic or heritable PAH. An increased number of patients received targeted therapy at the last follow-up compared with baseline. The 5-and 10-year survival rates of the entire cohort were 74.9% and 55.7%, respectively, with better survival in patients with CHD-associated PAH than in those with idiopathic or heritable PAH. Patients with low risk had better survival than those with high risk according to the simplified noninvasive risk score model with weight, function class, and echocardiographic right ventricular size, both at baseline and follow-up.INTERPRETATION: Patients with PPAH in China showed severely compromised hemody-namics with marked diagnostic delay. The long-term survival of PPAH is poor despite the increased usefulness of targeted drugs. The simplified noninvasive risk model demonstrated good performance for predicting survival in Chinese children with PAH.TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01417338; URL: www.clinicaltrials.gov CHEST 2023; 163(6):1531-1542

Where the congenital heart disease meets the pulmonary arterial hypertension, FLNA matters: a case report and literature review

Bilateral Periventricular Nodular Heterotopia Caused By A Novel Splicing Mutation In The Flna Gene In A Chinese Family

Genes in pediatric pulmonary arterial hypertension and the most promising BMPR2 gene therapy

Identification of a Novel Mutation in the BMPR2 Gene in a Pulmonary Arterial Hypertension Patient Using Next‐generation Sequencing

A familial case of diffuse periventricular nodular heterotopia identified prenatally: Filamin A defect as the probable cause

Coexistence of Low-Grade Fetal Adenocarcinoma and Adenocarcinoma in Situ of the Lung Harboring Different Genetic Mutations: A Case Report and Review of Literature

Clinical exome sequencing revealed that FLNC variants contribute to the early diagnosis of cardiomyopathies in infant patients.

Deficiency of Filamin A in Smooth Muscle Cells Protects Against Hypoxia‑mediated Pulmonary Hypertension in Mice.

Characteristics, treatments and survival of pulmonary arterial hypertension associated with congenital heart disease in China: Insights from a national multicenter prospective registry

Identification of rare variants in novel candidate genes in pulmonary atresia patients by next generation sequencing

Exome Sequencing Identifies Rare Variants in Novel Candidate Genes Associated with Pulmonary Atresia

Cardiovascular Involvement in Pediatric Laminopathies. Report of Six Patients and Literature Revision

A case report of a rare genetic mutation (LMNA-C.185G>C, p.Arg62Pro) associated with dilated cardiomyopathy in a Han Chinese child

Filamin A heart valve disease as a genetic cause of inherited bicuspid and tricuspid aortic valve disease

Diagnosis and treatment of pediatric pulmonary arterial hypertension

Novel FLNC variants in pediatric cardiomyopathy: an insight into disease mechanisms

Novel Compound Heterozygous PKLR Mutation Induced Pyruvate Kinase Deficiency With Persistent Pulmonary Hypertension in a Neonate: A Case Report

Reduction of Filamin C Results in Altered Proteostasis, Cardiomyopathy, and Arrhythmias

Emerging role of long non-coding RNAs in pulmonary hypertension and their molecular mechanisms (Review)

Molecular genetic framework underlying pulmonary arterial hypertension

Characteristics, Long-term Survival, and Risk Assessment of Pediatric Pulmonary Arterial Hypertension in China Insights From a National Multicenter Prospective Registry